Procept Biorobotics

Procept Biorobotics Dividend

Dividend of Procept Biorobotics (PRCT) as of Nov 21, 2026.

Dividend

0.00USD

Last updated:

How much dividend does Procept Biorobotics 2026 pay?

According to the latest status from November 2026, Procept Biorobotics paid a total of 0.00 USD per share in dividends within the last 12 months. With the current Procept Biorobotics price of 26.21 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Procept Biorobotics Dividends

Historical Procept Biorobotics Dividends
PaydateDividend

The Procept Biorobotics Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
0.00 USD
Jan 1, 2029 (e)
0.00 USD
Jan 1, 2030 (e)
0.00 USD
The Procept Biorobotics Dividend history
YEARDividendYoY
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Is the Procept Biorobotics Dividend Safe?

Procept Biorobotics has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Procept Biorobotics's Dividend Distributions

Procept Biorobotics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Procept Biorobotics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Procept Biorobotics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Procept Biorobotics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Procept Biorobotics Stock analysis

What does Procept Biorobotics do? PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare. Procept Biorobotics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Procept Biorobotics stock

Procept Biorobotics paid dividends every year for the past 0 years.

Procept Biorobotics is assigned to the 'Health' sector.

The dividends of Procept Biorobotics are distributed in USD.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Procept Biorobotics